- Counsel to a Fortune 50 company in multiple class action lawsuits filed after a vendor’s cybersecurity incident involving the alleged disclosure of protected health information.
- Represented a national medical group in multidistrict litigation arising from an alleged patient information breach, securing a very favorable resolution after fact and expert discovery and class certification, summary judgment, and Daubert briefing.
- Counsel to a lender in dozens of putative class actions arising out of a cybersecurity incident.
- Counsel to a flexible and rigid packaging company in a putative class action under the Illinois Genetic Privacy Information Act.
- Represented a fiberoptic cable manufacturing company in multiple class action lawsuits filed after a cybersecurity incident.
- Representing a temperature-controlled logistics company in multiple putative class actions arising out of cybersecurity incidents allegedly involving personally identifiable information of the company’s employees.
- Represented a quick-service retailer in numerous class action lawsuits brought by customers and financial institutions in the wake of a cybersecurity incident.
- Represented a network infrastructure provider in a class action lawsuit arising out of a ransomware incident, achieving an early resolution on favorable terms.
- Representing an educational services provider in False Claims Act litigation.
- Represented numerous retailers in False Claims Act litigation arising from alleged unclaimed property obligations.
- Represented a Fortune 100 company in a False Claims Act investigation.
- Represented an international material handling and logistics automation company in a products liability action.
- Phone: +1 404 881 4828
- Email: gavin.reinke@alston.com
Gavin Reinke focuses his practice on class action defense, with a particular emphasis on data security and privacy matters. He represents clients in some of the largest, most complex, and highest profile cybersecurity and data privacy class actions in the country. His experience includes defending companies in all phases of data breach litigation, from motions to dismiss through fact and expert discovery, in the class certification and summary judgment phases, and on appeal. He brings creative approaches to his clients’ disputes to achieve favorable resolutions. His experience also includes representing businesses in False Claims Act litigation and government investigations, products liability litigation, financial services litigation, and complex commercial disputes. The Best Lawyers in America® recognized Gavin as “Ones to Watch” in the area of Commercial Litigation for 2023–2025. Gavin currently serves on the firm’s Hiring Committee and oversees the Atlanta office’s summer associate program.
Before joining Alston & Bird, Gavin was a law clerk for the Honorable Phyllis A. Kravitch of the U.S. Court of Appeals for the Eleventh Circuit.
-
Class Action MDL Roundup March 26, 2025Class Action & MDL Roundup 2024 Q4 – We give you the benefit of the bargainIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the fourth quarter of 2024, an overdue audiobook suit is shelved, an old case gets new reps and new evidence, and face-swappers get SLAPPed. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.Class Action MDL Roundup March 26, 2025Class Action & MDL Roundup 2024 Q4 – We give you the benefit of the bargainIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the fourth quarter of 2024, an overdue audiobook suit is shelved, an old case gets new reps and new evidence, and face-swappers get SLAPPed. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup January 3, 2025Class Action & MDL Roundup 2024 Q3 – Our market research is sustainableIn this edition, it’s not a breach if it isn’t stolen, a greenwashing claim is washed away, and a district court’s denial swims with the fishes. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.Class Action MDL Roundup January 3, 2025Class Action & MDL Roundup 2024 Q3 – Our market research is sustainableIn this edition, it’s not a breach if it isn’t stolen, a greenwashing claim is washed away, and a district court’s denial swims with the fishes. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup October 2, 2024Class Action & MDL Roundup 2024 Q2 – We are administratively feasibleIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the second quarter of 2024, there can be only one claim form for many, broiler chickens are coming home to roost, and there is no conspiracy of memes. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.Class Action MDL Roundup October 2, 2024Class Action & MDL Roundup 2024 Q2 – We are administratively feasibleIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the second quarter of 2024, there can be only one claim form for many, broiler chickens are coming home to roost, and there is no conspiracy of memes. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup July 2, 2024Class Action & MDL Roundup 2024 Q1 – Reaching across the pondIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the first quarter of 2024, UK High Court weighs in on information asymmetry, debit is better than credit, and it helps to have a credible plaintiff. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.Class Action MDL Roundup July 2, 2024Class Action & MDL Roundup 2024 Q1 – Reaching across the pondIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the first quarter of 2024, UK High Court weighs in on information asymmetry, debit is better than credit, and it helps to have a credible plaintiff. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup March 21, 2024Class Action & MDL Roundup 2023 Q4 - Not all cases survive and advance
In this edition, student-athletes win an NIL round, Canadians in California isn’t personal (jurisdiction), and it’s only a duty to disclose when it’s material. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
Class Action MDL Roundup March 21, 2024Class Action & MDL Roundup 2023 Q4 - Not all cases survive and advanceIn this edition, student-athletes win an NIL round, Canadians in California isn’t personal (jurisdiction), and it’s only a duty to disclose when it’s material. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup December 18, 2023Class Action & MDL Roundup 2023 Q3 - Catching the class action waive(r)In the latest edition of the Class Action & MDL Roundup, covering notable class actions from the third quarter of 2023, a mistake is just a mistake, “99.99%” isn’t 100% clear, and faxes aren’t always free. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.Class Action MDL Roundup December 18, 2023Class Action & MDL Roundup 2023 Q3 - Catching the class action waive(r)In the latest edition of the Class Action & MDL Roundup, covering notable class actions from the third quarter of 2023, a mistake is just a mistake, “99.99%” isn’t 100% clear, and faxes aren’t always free. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup September 29, 2023Class Action & MDL Roundup 2023 Q2 – Ascertainability lives!In the latest edition of the Class Action & MDL Roundup, covering notable class actions from the second quarter of 2023, essential oils may need therapy, an ever-growing library goes nowhere, and one exclusion is specifically ambiguous. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.Class Action MDL Roundup September 29, 2023Class Action & MDL Roundup 2023 Q2 – Ascertainability lives!In the latest edition of the Class Action & MDL Roundup, covering notable class actions from the second quarter of 2023, essential oils may need therapy, an ever-growing library goes nowhere, and one exclusion is specifically ambiguous. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup June 30, 2023Class Action & MDL Roundup 2023 Q1 – We don’t discount confidentialityIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the first quarter of 2023, in pork we antitrust, paid time off is not pay, and if it’s free, it won’t cost you a TCPA violation. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.Class Action MDL Roundup June 30, 2023Class Action & MDL Roundup 2023 Q1 – We don’t discount confidentialityIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the first quarter of 2023, in pork we antitrust, paid time off is not pay, and if it’s free, it won’t cost you a TCPA violation. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
In the News June 23, 2023Law 360 | Ga. Panel Tosses Ex-Exec’s Conspiracy Case Against AttysSteve Collins, Sam Rutherford, Gavin Reinke, and Bryan Lutz are noted for representing Michael Smith and King & Spalding before the Georgia Court of Appeals.In the News June 23, 2023Law 360 | Ga. Panel Tosses Ex-Exec’s Conspiracy Case Against AttysSteve Collins, Sam Rutherford, Gavin Reinke, and Bryan Lutz are noted for representing Michael Smith and King & Spalding before the Georgia Court of Appeals.
-
Class Action MDL Roundup March 27, 2023Class Action & MDL Roundup 2022 Q4 – A “healthy” dose of litigationIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the fourth quarter of 2022, class actions gain an international flair, insurers have cures for COVID cases, and a remote presence is still a presence. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.Class Action MDL Roundup March 27, 2023Class Action & MDL Roundup 2022 Q4 – A “healthy” dose of litigationIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the fourth quarter of 2022, class actions gain an international flair, insurers have cures for COVID cases, and a remote presence is still a presence. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
Bar Admissions
- Georgia
Education
- Vanderbilt University (J.D., 2012)
- University of Florida (B.A., 2009)
Gavin Reinke, litigation senior associate, offers insight into the types of data breach class actions and the associated concerns to be aware of.